Risperidone-induced tardive dyskinesia

Movement Disorders

Volumn 12, Issue 1, 1997, Pages 119-121

  Gwinn, K A ^a   Caviness, J N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

AGED; ARTICLE; CASE REPORT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; PARKINSONISM; PRIORITY JOURNAL; RISK; TARDIVE DYSKINESIA; VIDEOTAPE;

EID: 0031018116     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120123     Document Type: Article

References (19)

1. 1 Casey De. Clozapine: neuroleptic‐induced EPS and tardive dyskinesia. Psychopharmacoloty (Berl) 1989 ; 99: S47–53.
2. 2 Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995 ; 15: 36S–44.
3. 3 Keltner NL. Risperidone: the search for a better antipsychotic. Perspect Psychiatr Care 1995 ; 31: 30–33.
4. 4 McKeith I, Ballard CG, Harrison RWS, Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995 ; 343: 699.
5. 5 Mahmood T, Clothier EB, Bridgman R. Risperidone‐induced extrapyramidal reactions. Lancet 1995 ; 346: 1226.
6. 6 Dave M. Tardive oculogyric crises with clozapine. J Clin Psychiatry 1994 ; 55 ; 264–265.
7. 7 Kurz M, Hummer M, Oberbauer H, Fleischhacker WW. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology (Berl) 1995 ; 118: 52–56.
8. 8 Andrew HG. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia. Can J Psychiatry 1994 ; 39: S70–80.
9. 9 Addington DE, Toews JA, Addinton JM. Risperidone and tardive dyskinesia: a case report. J Clin Psychiatry 1995 ; 56: 484–485.
10. 10 Ascher JA, Cole JO, Colin Jn, et al. Buproprion: a review of its mechanism of antidepressant activity [Review]. J Clin Psychiatry 1995 ; 56: 395–401.
11. 11 Cardoso FE, Jankovic J. Cocaine‐related movement disorders. Mov Disord 1993 ; 8: 175–178.
12. 12 LeWitt PA, Walters A, Henig W, McHale D. Persistent movement disorders induced by buspirone. Mov Disord 1993 ; 8: 331–334.
13. 13 Strauss A. Pral dyskinesia associated with buspirone use in an elderly woman. J Clin Psychiatry 1988 ; 49: 322–323.
14. 14 Hammerstad JP, Carter J, Nutt JG, Casten GC, Shrotriya RC, Alms DR, Temple D. Buspirone in Parkinson's disease. Clin Neuropharmacol 1986 ; 9: 556–560.
15. 15 Hauser RA, Olanow CW. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord 1993 ; 8: 512–514.
16. 16 Owens DG. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994 ; 55: 29–35.
17. 17 Casey De. Serotonergic and dopaminergic aspects of neuroleptic‐induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology (Berl) 1993 ; 112: S55–9.
18. 18 Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L‐dopa‐induced dyskinesias, neuroleptic‐induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993 ; 34: 713–38.
19. 19 Friedman E, Gianutsos G, Kuster J. Chronic fluphenazine and clozapine elicit opposite changes in brain muscarinic receptor binding: implications for understanding tardive dyskinesia. J Pharmacol Exp Ther 1983 ; 226: 7–12.